Table 1A.

Sample characteristics.

Subject	Gender	Age at surgery (year)	Disease duration at surgery (year)	LEDD pre-DBS (mg)	UPDRS pre-DBS meds-off (score)	UPDRS pre-DBS meds-on (score)	LEDD post-DBS (mg)	UPDRS post-DBS meds-off, stim-on (score)
wue2*	male	65	10	1100	40	23	800	19
wue3	male	61	18	2725	40	9	600	13
wue5*	male	67	17	1050	49	24	500	13
wue6	male	51	11	1133	47	12	180	9
wue7	male	61	10	650	43	24	220	19
wue9*	male	55	19	1200	50	11	730	16
wue11*	female	53	11	1300	55	4	460	9

Demographic and clinical information. Before surgery participants were tested after overnight withdrawal of all dopaminergic medications (meds-off). To evaluate the effect of levodopa (meds-on), the patient had turned into a good quality “on-state” upon receiving 1–1.5-times the levodopa-equivalent of the preoperative morning dose. After surgery, all patients were evaluated in meds-off condition but under chronically effective STN stimulation (meds-off, stim-on). *Indicates the four patients (i.e., wue2, 5, 9 and 11) who were able to complete the motor task (i.e., with both hands in the required amount of time, please refer to “Task and Experimental Design” in the “Materials and Methods Section”). DBS, deep brain stimulation; LEDD, levodopa equivalent daily dose; STN, subthalamic nucleus; UPDRS-III, Unified Parkinson Disease Rating Scale motor part.